{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:15:27Z","timestamp":1788668127045,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejca.2025.115693","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:45:20Z","timestamp":1755740720000},"page":"115693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study"],"prefix":"10.1016","volume":"229","author":[{"given":"Hiromi","family":"Nagashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0440-470X","authenticated-orcid":false,"given":"Tatsuro","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-9181","authenticated-orcid":false,"given":"Akihiko","family":"Miyanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7126-3153","authenticated-orcid":false,"given":"Hajime","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kisohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-0210","authenticated-orcid":false,"given":"Hisashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kanemaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-6392","authenticated-orcid":false,"given":"Eisaku","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-5946","authenticated-orcid":false,"given":"Naoki","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-6981","authenticated-orcid":false,"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-2720","authenticated-orcid":false,"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-1089","authenticated-orcid":false,"given":"Fumiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6468-9068","authenticated-orcid":false,"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-1943","authenticated-orcid":false,"given":"Makoto","family":"Maemondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115693_bib1","unstructured":"\u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer\u3009."},{"issue":"23","key":"10.1016\/j.ejca.2025.115693_bib2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"PROFILE 1014 investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2025.115693_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"ALEX trial investigators. Alectinib versus crizotinib in untreated ALK-Positive Non-Small-Cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2025.115693_bib4","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"CROWN trial investigators. First-line lorlatinib or crizotinib in advanced ALK-Positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.115693_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"21","key":"10.1016\/j.ejca.2025.115693_bib6","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-Positive Non-Small-Cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2025.115693_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115693_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-Mutant metastatic NSCLC: updated 5-Year survival rates and genomic analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115693_bib9","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115693_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115693_bib11","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2025.115693_bib12","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115693_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"FLAURA investigators. Osimertinib in untreated EGFR-Mutated advanced Non-Small-Cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115693_bib14","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","author":"Ramalingam","year":"2018","journal-title":"Oral Present ESMO"},{"issue":"5","key":"10.1016\/j.ejca.2025.115693_bib15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jtho.2024.12.029","article-title":"Amivantamab plus lazertinib in patients with EGFR-Mutant NSCLC after progression on osimertinib and Platinum-Based chemotherapy: results from CHRYSALIS-2 cohort a","volume":"20","author":"Besse","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2025.115693_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108040","article-title":"The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations","volume":"199","author":"Patil","year":"2025","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.115693_bib17","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.21873\/anticanres.12776","article-title":"Phase I study evaluating the combination of afatinib with carboplatin and pemetrexed after firstline EGFR-TKIs","volume":"38","author":"Watanabe","year":"2018","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2025.115693_bib18","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s10147-021-01947-3","article-title":"CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib","volume":"26","author":"Kato","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115693_bib19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ejca.2025.115693_bib20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1634\/theoncologist.2019-0101","article-title":"Genetic profiling of Non-Small cell lung cancer at development of resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq analysis of circulating tumor DNA","volume":"24","author":"Otsubo","year":"2019","journal-title":"Oncologist"},{"issue":"27","key":"10.1016\/j.ejca.2025.115693_bib21","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2012.45.0981","article-title":"LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both","volume":"31","author":"Katakami","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115693_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115693_bib23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115693_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"West Japan oncology group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2025.115693_bib25","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"North-East Japan study group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.ejca.2025.115693_bib26","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115693_bib27","first-page":"629","article-title":"AURA3 investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive lung cancer","volume":"376","author":"Mok","year":"2017"},{"issue":"1","key":"10.1016\/j.ejca.2025.115693_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"MARIPOSA-2 investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115693_bib29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdv063","article-title":"Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005\/TCOG0902","volume":"26","author":"Sugawara","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115693_bib30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2025.115693_bib31","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE investigator group. Tribute: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115693_bib32","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2025.115693_bib33","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/JCO.2011.40.1315","article-title":"Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial","volume":"30","author":"J\u00e4nne","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115693_bib34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1470-2045(13)70254-7","article-title":"Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial","volume":"14","author":"Wu","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115693_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"North-East Japan study group. Gefitinib alone versus gefitinib plus chemotherapy for Non-Small-Cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115693_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cllc.2020.09.023","article-title":"A phase II study of osimertinib combined with platinum plus pemetrexed in patients with EGFR-Mutated advanced Non-Small-cell lung cancer: the OPAL study (NEJ032C\/LOGIK1801)","volume":"22","author":"Asahina","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2025.115693_bib37","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"FLAURA2 investigators. Osimertinib with or without chemotherapy in EGFR-Mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2025.115693_bib38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2025.115693_bib39","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"IMpower150 study group. Atezolizumab for First-Line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.115693_bib40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2025.115693_bib41","article-title":"A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)","volume":"197","author":"Watanabe","year":"2023","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.ejca.2025.115693_bib42","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with Third-Generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2025.115693_bib43","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/cas.12980","article-title":"Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: what is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?","volume":"107","author":"Banno","year":"2016","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.ejca.2025.115693_bib44","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115693_bib45","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/cas.16199","article-title":"Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression","volume":"115","author":"Onda","year":"2024","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.ejca.2025.115693_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.115693_bib47","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115693_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.ejca.2025.115693_bib49","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ejca.2025.115693_bib50","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdw322","article-title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials","volume":"27","author":"Yang","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115693_bib51","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/cas.12723","article-title":"Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: subgroup analysis of LUX-Lung 3","volume":"106","author":"Kato","year":"2015","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.ejca.2025.115693_bib52","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent TP53 mutations facilitate resistance evolution in EGFR-Mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J Thorac Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925004757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925004757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T09:50:42Z","timestamp":1772877042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925004757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"alternative-id":["S0959804925004757"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115693","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115693"}}